Cannabis Sativa, Inc. (OTCMKTS: CBDS) is a U.S.-based company engaged in the development, production and distribution of hemp-derived cannabinoid products. Originally founded in the early 2000s, the company rebranded in 2018 to focus exclusively on non-intoxicating cannabinoid formulations. Headquartered in San Diego, California, Cannabis Sativa maintains extraction and processing facilities that adhere to current Good Manufacturing Practices (cGMP) standards, ensuring consistency and quality across its product lines.
The company’s core business activities center on proprietary extraction and purification technologies designed to isolate bioactive hemp compounds such as cannabidiol (CBD), cannabidiolic acid (CBDA) and select minor cannabinoids. Its product portfolio spans bulk cannabinoid isolates, custom-formulated tinctures and finished consumer goods for use in nutraceutical, cosmeceutical and pharmaceutical applications. Through in-house analytical laboratories, Cannabis Sativa oversees every stage of production, from raw material testing to the finished product, to meet strict safety and potency benchmarks.
Cannabis Sativa serves markets throughout North America, with distribution channels in key U.S. states where hemp and hemp-derived products are legal under federal and state regulations. The company has also pursued export opportunities in Europe and Asia, aligning with jurisdictions that permit cannabidiol products for wellness and personal care. By forging partnerships with licensed growers and research institutions, Cannabis Sativa seeks to expand its geographic footprint while navigating evolving regulatory frameworks.
The leadership team at Cannabis Sativa includes Chief Executive Officer Eddie Dowling, whose background in agricultural biotechnology drives the company’s innovation agenda, and Chief Scientific Officer Dr. Miriam Jackson, a pharmacologist with experience in natural product drug development. The board of directors comprises industry veterans in compliance, manufacturing and marketing, reflecting the company’s emphasis on regulatory adherence and scalable growth. Looking ahead, Cannabis Sativa plans to advance its product pipeline through targeted research collaborations and strategic licensing agreements.
AI Generated. May Contain Errors.
